Cytofluorimetric assay to investigate variability in blinatumomab in vitro response

Cytofluorimetric assay to investigate variability in blinatumomab in vitro response

Background: The T-cell engager antibody blinatumomab (BlincytoT⁢M) represents a promising rescue therapy for relapsed/refractory CD19+ acute lymphoblastic leukemia (B-ALL), although ~20–30% of patients still do not respond to treatment. Blinatumomab creates a tight synapsis between CD3+ T-lymphocyte...

Full description

Bibliographic Details
Main Authors: Stefania Braidotti, Raffaella Franca, Marilena Granzotto, Elisa Piscianz, Alberto Tommasini, Marco Rabusin, Gabriele Stocco, Giuliana Decorti
Format: Article
Language:English
Published: IMR Press 2022-01-01
Series:Frontiers in Bioscience-Landmark
Subjects:
pediatric acute lymphoblastic leukemia
blinatumomab
in vitro cytofluorimetric assay
pax5
Online Access:https://www.imrpress.com/journal/FBL/27/2/10.31083/j.fbl2702039

Internet

https://www.imrpress.com/journal/FBL/27/2/10.31083/j.fbl2702039

Similar Items